The largest database of trusted experimental protocols

23 protocols using iacs 010759

1

Ovarian Cancer Spheroid Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ascites‐derived spheroids from five different high‐grade serous ovarian cancer patients were enriched with 15 µm cell strainers as described before. Approximately 1 × 104 counted cells were seeded in each well of a 96‐well plate resuspended in MCDB medium (90 µL/per well). Then, a total of 10 µL MCDB medium containing metformin (Merck KGaA; Darmstadt, Germany), cisplatin (Pharmacy, University clinic Hamburg‐Eppendorf, Germany), IACS010759 (Selleck Chemicals, #S8731), metformin + cisplatin or IACS 010759 + cisplatin were added to each well to reach following final concentrations: 0, 5 mm metformin, 0, 3.3, 33.3 µm cisplatin and 50 nm IACS 010759. Each treatment condition was plated in triplicates. After 48 h, 80 µL volume of spheroids from each well was mixed with equal amount of CellTiter‐Glo® Luminescent Cell Viability Assay Chemistry (Promega; Madison, Wisconsin, USA) in a white 96 Well Polystyrene Microplate (Greiner; Bio‐one, Kremsmünster, Austria) and shacked for 10 min. After 20 min further incubate at room temperature, the cell viability was measured using a luminescence reader (BioTek; Winooski, VT, USA).
+ Open protocol
+ Expand
2

Evaluating apoptosis and proliferation in T-cell lymphoma lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Established T-cell lymphoma lines were used for drug assays, including Myla (MF; Sigma Aldrich Cat# 95051032), HH (MF - leukemic phase; ATCC Cat# CRL-2105), and Hu78 (SS; ATCC Cat# TIB-161), Jurkat (ATLL) and MJ (ATLL; ATCC Cat# 8294). For the apoptosis assay, indicated cell lines were seeded with the density of 1×105 cells/well in 96-well plate and treated with 8 nM of IACS-010759 (SelleckChem# S8731). At day 5, cells were harvested and stained with Annexin V and PI following manufacture’s protocol (Biolegend Cat# 640914). Annexin V+PI+ population was gated on Singlet population using FlowJo 10 software (RRID:SCR_008520). For cell proliferation assay, indicated cell lines were seeded with the density of 1×104 cells/well in 96-well plate and treated with different dose of MYCi975 (MedChemExpress Cat# HY-129601) for 5 days. At day 5, cells were incubated with MTS reagent following manufacture’s protocol (Promega Cat#G3580). Absorbance at OD490 nm was recorded and percentage of growth were normalized to vehicle control. IC50 was calculated based on curve fitting result using non-linear regression function of GraphPad Prism 8 (RRID:SCR_002798).
+ Open protocol
+ Expand
3

Metabolic Modulation in Tumor Spheroids

Check if the same lab product or an alternative is used in the 5 most similar protocols
B16OVA.HRE and MC38.HRE spheroids were treated with OXPHOS inhibitors 24 h after seeding. The following OXPHOS inhibitors were used for treatment: IACS-010759 (1, 0.33, 0.11 and 0.037 µM, Selleckchem), metformin (9, 3, 1 and 0.33 mM, Sigma-Aldrich), atovaquone (30, 15, 7.5 and 3.75 µM, Sigma-Aldrich), mito10-atovaquone (30, 15, 7.5 and 3.75 µM) [16 (link)], Mito-PEG5-atovaquone (30, 15, 7.5 and 3.75 µM) [21 ], tamoxifen (5, 2.5, 1.25 and 0.625 µM, Sigma-Aldrich (H7904)) and MitoTam (5, 2.5, 1.25 and 0.625 µM) [27 (link), 28 (link)]. Control spheroids were treated with 0.2% DMSO.
+ Open protocol
+ Expand
4

Maintenance of Cell Lines for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
OPM-1, KMS-11, BJAB, SUDHL10, U2932, HLY1, and HT cells were maintained in RPMI-1640 media containing 10% fetal bovine serum (FBS). HEK293T cells were maintained in Dulbecco’s modified Eagle’s media (DMEM) containing 10% FBS. HEK293T cells were purchased from ATCC. B-cell cancer cell lines were kindly provided by Dr. Laura Pasqualucci, Dr. Michele Pagano and Dr. Yibin Yang. Cell line authentication was not performed as cells were not listed in the commonly misidentified category. All cell lines were free of mycoplasma contamination (MycoAlert kit, Lonza). Cell lines were passaged for less than 6 months after receipt or resuscitation. The following drugs were used: MG132 (Peptides International, #IZL-3175-v; 10 μM final concentration), MLN4924 (EMD Millipore, #505477; 5 μM final concentration), cycloheximide (Sigma-Aldrich, #C7698; 20 mg/mL final concentration), Doxycycline hyclate (Sigma-Aldrich, #D9891; 1 ng/mL or 1 mg/mL final concentration), and IACS-010759 (Selleck Chemicals, #S8731), puromycin (Sigma-Aldrich, 0.5–1 μg/ml final concentration), hygromycin B (EMD Millipore, #400052, 100–200 μg/mL), zeocin (100–250 μg/mL), and blasticidin S HCl (Gibco, #R21001, 3–15 μg/mL). CRISPR-derived HEK293T FBXW7–/– clones were selected using single cell cloning in 96-well plates.
+ Open protocol
+ Expand
5

Metabolic Regulators and Cell Death

Check if the same lab product or an alternative is used in the 5 most similar protocols
IACS-010759 (S8731), CB839 (S7655), oligomycin A (S1478), rotenone (S2348), BAY-876 (S8452), and cisplatin (S1166) were purchased from Selleck Chemicals (Houston, Texas, USA). Alanine (550-001-EG) was obtained from Wisent Bio (Montreal, QC, Canada). 13C5-Glutamine (CLM-1822), 13C6-Glucose (CLM-1396), were from Cambridge Isotopes Laboratories (Tewksbury, MA). Metformin (#13118) and Phenformin (#14997) were from Cayman Chemical (Ann Arbor, MI, USA). Dimethyl-α-ketoglutarate (DMKG, #349631) was from Sigma (Oakville, ON, Canada). Caspase3/7 green dye (4440) was from Sartorius (Goettingen, Germany). Antibodies against HSP90 (H-114, 1:1,0000) and β-Actin (Cat# sc-47778, 1:1,0000) were from Santa Cruz Biotechnology (Dallas, TX, USA); antibodies against cleaved PARP (Cat# 5625, 1:1,000) and SMARCA2 (Cat# 11996, 1:1,000) were from Cell Signaling (Danvers, MA, USA); antibody against SMARCA4 (A300-813A, 1:1,000) and (ab110641, 1:5000) were from Bethyl Laboratories (Montgomery, TX, USA) and Abcam (Tornoto, ON, Canada), respectively; antibody against SLC2A1 (ab15309, 1:1,000) was from Abcam; antibody against SLC38A2 (BMP081, 1:1,000) was from MBL (Woburn, MA, USA). Antibodies for immunohistochemistry are listed in the corresponding method section below.
+ Open protocol
+ Expand
6

Cell Line Characterization and Drug Testing

Check if the same lab product or an alternative is used in the 5 most similar protocols
HR-proficient OVCAR-8 (D. Scudiero, National Cancer Institute, Frederick, MD) and OVCAR-8-DR-GFP cells (14 (link)), the BRCA1-mutant COV362 cells (Robert van Waardenburg, University of Alabama at Birmingham, Birmingham, AL), prostate cancer PC3 (Haojie Huang, Mayo Clinic), and breast cancer MDA-MB-231 cells (Zhenkun Lou, Mayo Clinic) were cultured in RPMI-1640 media (Corning) supplemented with 8% fetal bovine serum (Millipore) and maintained in a humidified 5% CO2 incubator at 37 °C. All cells were authenticated by autosomal STR profiling (University of Arizona Genetics Core) and were free of Mycoplasma contamination as determined by testing with a MycoAlert Mycoplasma Detection Kit (catalog no. LT07-118, Lonza) every 6 months. Cell lines reinitiated from cryopreserved stocks every 3 to 6 months.
Ceritinib used for cell culture experiments as well as olaparib, veliparib, IACS-010759, and linsitinib were obtained from Selleck Chemicals. The Ceritinib used for mouse studies was provided by Novartis. Cisplatin was obtained from Teva Pharmaceutical Industries. SL0101 was purchased from Millipore.
+ Open protocol
+ Expand
7

Ceramide Nanoliposome Anti-Cancer Formulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
C6-ceramide (N-hexanoyl-D-erythro-sphingosine) was from Avanti Polar Lipids, Alabaster, AL. Ceramide nanoliposomes (CNL) were a generous gift from Keystone Nano, Inc. Control (ghost) formulations included all liposomal ingredients except C6- ceramide. Propidium iodide (PI) was obtained from Life Technologies/Thermo Fisher, Carlsbad, CA. SK1-i, a SPHK1 inhibitor, was from Enzo, Farmingdale, NY. Vincristine sulfate was purchased from LC Laboratories, Woburn, MA. Daunorubicin (DNR) and venetoclax (Vclax) were from R&D Systems, Minneapolis, MN. Metformin and phenformin were purchased from Sigma. IACS-010759 was purchased from SelleckChem. com (Cat # S8731). All chemicals for mitochondrial analysis were purchased from Sigma. D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) was purchased from Cayman, Ann Arbor, MI.
+ Open protocol
+ Expand
8

Cell line culture and authentication

Check if the same lab product or an alternative is used in the 5 most similar protocols
HR-proficient OVCAR-8 (D. Scudiero, National Cancer Institute) and OVCAR-8-DR-GFP cells (14 (link)), the BRCA1-mutant COV362 cells (Robert van Waardenburg, University of Alabama at Birmingham, Birmingham, AL), prostate cancer PC3 (Haojie Huang, Mayo Clinic), and breast cancer MDA-MB-231 cells (Zhenkun Lou, Mayo Clinic) were cultured in RPMI-1640 media (Corning) supplemented with 8% FBS (Millipore) and maintained in a humidified 5% CO2 incubator at 37°C. All cells were authenticated by autosomal STR profiling (University of Arizona Genetics Core) and were free of Mycoplasma contamination as determined by testing with a MycoAlert Mycoplasma Detection Kit (catalog no. LT07-118, Lonza) every 6 months. Cell lines were reinitiated from cryopreserved stocks every 3 to 6 months.
Ceritinib used for cell culture experiments as well as olaparib, veliparib, IACS-010759, and linsitinib were obtained from Selleck Chemicals. The Ceritinib used for mouse studies was provided by Novartis. Cisplatin was obtained from Teva Pharmaceutical Industries. SL0101 was purchased from Millipore.
+ Open protocol
+ Expand
9

Xenograft Model for IACS-010759 Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Xenograft experiments were approved by the Animal Care and Use Committee at the University of Pennsylvania. KELLY cells (3 × 106) were injected in a 1:1 mixture of PBS and Matrigel (Corning; #356234) in a final volume of 200 μL into both flanks of female Balb/c nude mice (Charles River Laboratories: #194). Flank tumors were measured every other day by electronic calipers and tumor volumes were calculated as (π/6)(length × width2). Once the tumor reached approximately 100 mm3, mice were randomly assigned to two groups and treated with vehicle or IACS-010759 (Selleck-chem: #S8731). The vehicle (containing 0.5% Methyl Cellulose; viscosity: 4000cP; Sigma: no. M0512) or IACS-010759 (7.5 mg/kg per dose) was given to mice by oral gavage once daily on a 5-day on 2-day off regimen as described (24 (link)). At the endpoint of the experiments, animals were euthanized by CO2 inhalation.
+ Open protocol
+ Expand
10

Culturing and Treating Primary Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human PBMCs were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Biowest), 100 U penicillin–streptomycin (Gibco), and 2 mM L-Glutamine (Gibco). PDECs were cultured in MammoCult (STEMCELL Technologies), and the MammoCult media was supplemented with MammoCult proliferation supplement #05622 (STEMCELL Technologies), 20 µg/mL gentamicin (Sigma), 0.1 µg/mL amphotericin B (Biowest) and 10,000 U/mL penicillin/streptomycin (Lonza). Cells and PDECs were grown in a humidified incubator at 37°C under 5% CO2, and atmospheric oxygen levels.
PDECs were treated with 25 ul/mL anti-CD3/CD28/CD2 (STEMCELL Technologies), 100 ug/mL atezolizumab (Selleck Chemicals), 50 ug/mL pembrolizumab (MedChem), 10–100 nM Venetoclax (MedChem Express), 5–10 mM metformin (MedChem Express), 10–50 nM paclitaxel (MedChem Express), 1–2.5 nM IACS-010759 (Selleck Chemicals), 10–30 nM rotenone (Sigma-Aldrich), and 10 nM-1 uM A-769662 (Sigma-Aldrich), 100 ng/mL lipopolysaccharide (LPS).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!